Adagio Medical (ADGM) announced the completion of enrollment of the FULCRUM-VT FDA investigational device exemption study evaluating the company’s vCLAS Cryoablation System for ablation of monomorphic ventricular tachycardia. The vCLAS System, which has been granted breakthrough device designation by the FDA, is built on the company’s proprietary ultra-low temperature cryoablation technology platform.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADGM: